您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > MLS-573151
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
MLS-573151
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
MLS-573151图片
CAS NO:10179-57-4
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
MLS-573151 (MLS000573151) 是一种选择性 GTPase Cdc42 抑制剂，EC50 为 2 μM。
Cas No.10179-57-4
别名MLS000573151
化学名4-(4,5-dihydro-3,5-diphenyl-1H-pyrazol-1-yl)-benzenesulfonamide
Canonical SMILESNS(C(C=C1)=CC=C1N2C(C3=CC=CC=C3)CC(C4=CC=CC=C4)=N2)(=O)=O
分子式C21H19N3O2S
分子量377.5
溶解度≤20mg/ml in DMSO;30mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

MLS-573151 is a specific and cell permeable inhibitor of Cdc42 [1].

Cdc42 is a small GTPase of the Rho family involved in regulating signaling pathways that control diverse cellular functions such as cell morphology, cell migration, cell cycle progression and endocytosis [2].

In vitro: MLS-573151 was a specific, cell permeable inhibitor of Cdc42 with an IC50 of 2 μM [1]. MLS-573151 showed no effect on other GTPases, including the related Rho family members RhoA, Rac1, and Rac2. MLS-573151 functioned by blocking the binding of GTP to Cdc42 [1]. In marrow-derived mesenchymal stem cells, MLS-573151 showed no effect on cell migration [3].

References:
[1] Surviladze Z, Waller A, Wu Y, et al.  Identification of a small GTPase inhibitor using a high-throughput flow cytometry bead-based multiplex assay[J]. Journal of biomolecular screening, 2010, 15(1): 10-20.
[2] Qadir M I, Parveen A, Ali M.  Cdc42: Role in Cancer Management[J]. Chemical biology & drug design, 2015, 86(4): 432-439.
[3] Wang L, Yang L, Tian L, et al.  Cannabinoid Receptor 1 Mediates Homing of Bone Marrow‐Derived Mesenchymal Stem Cells Triggered by Chronic Liver Injury[J]. Journal of cellular physiology, 2017, 232(1): 110-121.